Breath Biopsy with TD-GC-Orbitrap: a non-invasive approach for disease detection

Authors: Dominic Roberts¹, Cristian Cojocariu¹, Kayleigh Arthur², Jonathan Lawson²; ¹Thermo Fisher Scientific, Runcorn, UK; ²Owlstone Medical, Cambridge, UK

Keywords: Breath Biopsy, early detection, respiratory disease, biomarkers, Thermal Desorption, Gas Chromatography, Orbitrap Technology, clinical research

Introduction – Workflow to early disease detection using breath samples

The concept of using breath samples to identify changes linked with health and disease is not new. For decades researchers have been investigating the composition of breath, including via measurement of the volatile organic compounds (VOCs) in exhaled air, to examine potential changes in our biology and health. In the genomics era, new technologies and an increased emphasis on high-throughput biological analysis and metabolomics have expanded the breath research field. As Figure 1 highlights, breath testing offers a straightforward, non-invasive way to monitor our biology, providing a tool for the early detection of diseases and optimisation of treatments through precision medicine, as such interest in breathomics has grown rapidly¹.

Breath Biopsy™ represents an entirely new way to measure the chemical makeup of breath. Unlike liquid and tissue biopsies, which require blood or tissue samples to be taken, Breath Biopsy provides a non-invasive and pain-free approach to reliable and accurate testing. One of the key benefits of using breath for early detection is that, unlike genetic tests, it is based on current metabolic activities. This means the results highlight present metabolomic state, not just a life-long predisposition towards specific health issues. Metabolism is also the first to change in a disease, before damage or phenotypic symptoms occur, therefore it’s also the most appropriate way to detect diseases in their earliest stages. The extent that this is possible depends on sensitivity of detection, which is one of the key benefits of using high resolution accurate mass leveraging Orbitrap™ technology for Breath Biopsy.

Figure 1. Overview of the contribution of both exogenous and endogenous factors to the composition of a breath sample. This is important as all factors can influence an individual’s health.
By determining the chemical compounds present in breath, we can:

- **Identify** critical biomarkers of disease
- **Detect** diseases in their earliest stages
- **Monitor** responses to drugs and other therapies
- **Assess** exposure to hazardous substances

VOCs are gaseous molecules that can be sampled quickly and non-invasively from breath. Many VOCs in breath are produced as the end product of metabolic processes within the body. It is well understood that disease drives metabolic changes and these can produce particular patterns of VOCs characteristic of each disease. Therefore, volatile metabolic biomarkers are often the earliest signs of illness, making Breath Biopsy a valuable option for early detection, prognosis and monitoring. Similarly, differences in metabolism characterise different disease phenotypes and so can be used to determine optimal treatments for individual patients.

**How are VOCs sampled in breath?**

VOCs produced throughout the body are subsequently deposited into the bloodstream from where they reach other parts of the body. In lungs, gases are exchanged between circulating blood and inhaled air. Alongside oxygen and carbon dioxide, volatile metabolites also pass efficiently from the blood into breath. These VOCs are then exhaled and provide a source of biomarkers directly linked to the body’s metabolism.

Breath Biopsy non-invasively collects and measures VOC biomarkers from a subject’s breath. As blood circulates throughout the body before returning to the lungs, the VOC biomarkers in breath provide a snapshot of a person’s metabolome. As shown in Figure 2, it takes roughly 1 minute for blood to flow around the entire circulatory system. By sampling breath for a minute or longer, even very low levels of systemic VOC biomarkers can be collected, pre-concentrated and analyzed.

**The complete analytical solution**

Figure 3 outlines the process from sample collection, analysis and results that is provided by this unique workflow solution. Breath collection and pre-concentration is carried out using the ReCIVA™ Breath Sampler, which ensures reliable, reproducible collection and pre-concentration of a wide range of VOCs. In the Breath Biopsy Collection Station, ReCIVA is coupled to the CASPER™ Portable Air Supply which filters the air subject’s inhale to reduce background VOCs from external sources. The VOCs from the exhaled breath are captured on Breath Biopsy Cartridges, which can then be analyzed using GC Orbitrap high resolution mass spectrometry to determine the VOC profile. Thermo Scientific™ Compound Discoverer™ 3.2 software can be used to pinpoint the VOCs of interest (biomarkers) during the discovery phase and Thermo Scientific™ Chromeleon™ software can be used for targeted qualitative or quantitative analysis of known compounds in more routine screening tests.
Sample collection
The Breath Biopsy platform includes the ReCIVA Breath Sampler (Figure 4), which was designed in collaboration with leading experts in the breathomics field to provide a standardized method to collect exhaled breath samples. Using internal, fast response carbon dioxide and pressure sensors, ReCIVA can monitor patient breathing patterns in real time that allows tracking of a subject’s breathing patterns. By learning breath patterns, the Breath Biopsy Collect Software can turn the sampling pumps on/off making it possible for ReCIVA to collect specific breath fractions (e.g. alveolar-enriched, upper airway or total breath) without the need for complex breath manoeuvres. The selected fractions of exhaled breath VOCs are collected on a Breath Biopsy Cartridge for later analysis. Replicate breath samples and/or different breath fractions can be obtained in a single collection event.

The stability of compounds in stored tubes will vary between VOC species and on which sorbent(s) they are adsorbed on. Evidence suggests that for some compounds minimal changes are observed in Tenax TA and carbograph tubes refrigerated for a period of 2 weeks². Storage at -80 °C for up to 1.5 months has been shown to result in no discernible changes to samples kept on Tenax TA/Carbograph multi-bed tubes³. Further work is underway to investigate VOC stability.
Confidence in compound detection at all levels

The analytical solution utilized here is to link breath sample collection, thermal desorption and measurement by high resolution accurate mass (HRAM) spectrometry to provide a comprehensive profile of a breath sample. The key benefits of using GC-Orbitrap high resolution mass spectrometry with Breath Biopsy is the wide dynamic range, high mass resolving power, and the mass accuracy, which enables detection and quantification at low and high concentrations as well as fast and confident compound identifications. Breath analysis is often limited by number of samples and it is essential to collect both quantitative and qualitative information from this single analysis. Breath Biopsy has the capability to enable parallel targeted and untargeted/discovery analysis allowing the study of known and potential novel biomarkers. ReCIVA also collects multiple parallel samples which can support biomarker identification and validation. In addition, as Figure 5 demonstrates, breath samples contain very high and ultra-trace (femtograms) levels of compounds in the same sample and so it’s critical to have access to high quality data across a wide abundance range. The dynamic range of over six orders is what makes this possible with GC Orbitrap technology.

With full scan HRAM data there is also the option for retrospective analyses, returning to the data at a later stage to ask different questions of the sample. It’s possible to compare results, increase the number of samples, target specific compounds, and perform quantitation. Essentially it provides a complete profile of the sample at a particular time point and this helps to build an understanding of what is normal, and critically, when something is different with a sample. Having flagged the difference it’s possible to take a deeper dive into the data and confidently identify associated volatile biomarkers. When combined with additional phenotypic information, this represents a powerful virtual subject profile which can then be returned to later and used to hypothesis test or to augment trials with additional in silico samples.

In this study, we look at samples from smoking and non-smoking individuals to detect differences between the samples and make confident compound identifications.

Figure 5. TIC of multiple breath samples demonstrating the wide range in concentrations encountered in breath analysis. Compounds present across 5 orders of magnitude.
**Experimental Samples**
Breath samples (1500 mL on-tube) were collected using the ReCIVA Breath Sampler, which captures and pre-concentrates VOCs onto Breath Biopsy Cartridges (Owlstone Medical Ltd.). Quality control samples consisted of a custom 40-compound mixture prepared in methanol (1, 100 and 200 ppm median concentration).

**Data acquisition**
Samples were dry purged to remove excess water and desorbed using an autosampler equipped with a focusing trap (Markes International) and transferred onto a 30 m x 0.32 mm x 3.00 µm column (Quadrex) using splitless injection. Chromatographic separation was achieved via a programmed method on a Thermo Scientific™ TRACE™ 1310 GC oven equipped with a Thermo Scientific™ TriPlus™ RSH™ headspace autosampler. Mass spectral data were acquired using a Thermo Scientific™ Q Exactive™ GC Orbitrap mass spectrometer having both variable-EI and CI capabilities. Details of the experimental parameters are shown in Table 1. Data was processed using Compound Discoverer 3.2 for sample profiling, statistical comparison and compound identification by spectral matching.

**Results Smoking-related volatile markers**
Untargeted discovery analysis is an important aspect of the Breath Biopsy workflow for metabolomics analysis and biomarker discovery. The crucial challenge is reliable and reproducible deconvolution of fragmentation patterns of TD-GC-MS analysis. The software used here is Compound Discoverer 3.2 which incorporates GC deconvolution and statistical analysis into a single software and includes option to embed custom scripts (python and R). In this example study a small set of 12 breath samples were analyzed on the platform and above-mentioned software tools were used for generating a list of reliable features for each sample. Samples were divided into three groups based on the subject’s smoking history: never smoked (n=3), current smokers (n=4) and ex-smokers (n=5). Based on smoking-related breath markers previously reported in literature, a custom 6-compound library was created and used for quantitation of these markers in each of the breath samples. Fold changes relative to the non-smoker group for each marker and sample were calculated using extracted peak area responses. Figure 6 shows low fold changes for most of the targeted smoking-markers in all three groups, suggesting low correlation between smoking behavior and the reported markers (e.g. ethylbenzene boxplot). High fold changes are observed for 2,5-dimethylfuran and toluene in the current group of smokers, suggesting correlation with smoking behavior for these two markers (e.g. toluene boxplot).

<table>
<thead>
<tr>
<th>TD parameter</th>
<th>Pre-purge time (min)</th>
<th>0.1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trap in line (Y/N)</td>
<td>Yes</td>
<td></td>
</tr>
<tr>
<td>Pre-purge trap flow (mL/min)</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>Tube desorb time (min)</td>
<td>10.0</td>
<td></td>
</tr>
<tr>
<td>Tube desorb flow (mL/min)</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>Tube desorb temperature (˚C)</td>
<td>210</td>
<td></td>
</tr>
<tr>
<td>Trap desorb time (min)</td>
<td>3.0</td>
<td></td>
</tr>
<tr>
<td>Trap purge flow (mL/min)</td>
<td>50</td>
<td></td>
</tr>
<tr>
<td>Trap high (˚C)</td>
<td>250</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>MS parameter</th>
<th>Transfer line temperature (˚C)</th>
<th>250</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ionization type</td>
<td>El, CI (methane)</td>
<td></td>
</tr>
<tr>
<td>Ion source temperature (˚C)</td>
<td>280</td>
<td></td>
</tr>
<tr>
<td>Electron energy (eV)</td>
<td>35, 70</td>
<td></td>
</tr>
<tr>
<td>Acquisition mode</td>
<td>Full scan</td>
<td></td>
</tr>
<tr>
<td>Mass range (m/z)</td>
<td>35–350</td>
<td></td>
</tr>
<tr>
<td>Resolving power (FWHM at m/z 200)</td>
<td>60,000</td>
<td></td>
</tr>
<tr>
<td>Lock masses (m/z)</td>
<td>207.03235; 281.05114; 355.06994</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>GC parameter</th>
<th>Operation mode</th>
<th>Constant flow</th>
</tr>
</thead>
<tbody>
<tr>
<td>Carrier gas</td>
<td>Helium; 3.00 mL/min</td>
<td></td>
</tr>
<tr>
<td>Temperature ramp (˚C)</td>
<td>40–250</td>
<td></td>
</tr>
</tbody>
</table>
Breath sample data (n=12) show high fold changes for 2,5-Dimethylfuran and Toluene in samples from current smokers and suggests correlation of the markers to smoking behavior.

The collection of HRAM data is crucial in metabolomics studies where low-concentration analytes are to be detected in a complex breath matrix. Figure 7 shows data acquisition with sub-1 ppm mass accuracy achieved over the full chromatographic peak. The outstanding mass accuracy greatly improves peak deconvolution and helps differentiate analytes of interest from matrix ions by allowing for very narrow mass extraction windows. The high linear dynamic range of the Orbitrap guarantees stable ion ratios even at high sample concentrations, which improves deconvolution, compound identification and the generation of custom libraries. As shown, the ion ratio \( m/z 95: m/z 81 \) is stable at both the apex of the peak and inflection points.

**Deconvolution and library matching**

Peak deconvolution of breath data results in a peak features list containing typically >500 entries, which can be either true chromatographic peaks associated to chemicals in breath as well as compounds coming from background. Reduction of the number of background matrix compounds and condensing of these feature lists is essential for generating high-quality data sets that can be used in untargeted metabolomics approaches. Together with spectral matching (e.g. against reference NIST spectra; SI score), Compound Discoverer calculates High Resolution Filtering (i.e. HRF) scores from high-accuracy EI data that allow for more precise compound identification.

**Figure 7.** Sub-1 ppm mass accuracy can be achieved across the width of chromatographic peaks. Ion ratio stability can be guaranteed at varying concentrations across the width of the chromatographic peaks.
1-Nonene
Score 99.7
SI 993, RSI 995
HRF 99.3375, RHRF 99.3441

D-Limonene
Score 99.2
SI 972, RSI 976
HRF 99.1701, RHRF 99.1701

Figure 8. Peak deconvolution is performed and spectral matching of compounds to a high resolution compound library.

Similarly, retention index information obtained using e.g. alkanes generally present in breath samples adds to the confidence in unknown compound identification and can be used to distinguish between closely-related library matches.

Ionization and fragmentation
The production of characteristic fragment ion spectra under EI conditions in GC-MS typically allow for the identification of unknown analytes. For closely related analytes with similar or identical fragmentation, EI data is often insufficient to lead to a conclusive identification. Alternative, softer ionization methods such as positive/negative chemical ionization can be explored to aid identification of unknowns as they lead to formation of higher \( m/z \) ions (e.g. \([M+H]^+\)). These can improve differentiation between compounds from specific classes such as alkanes and terpenes.

More complimentary data sets can be obtained by use of VeV ionisation or variable C-Trap voltages. Using these settings EI-like fragment spectra are obtained and higher abundance is observed for the molecular ion \([M]^+\).

Into the routine
Having isolated a list of specific marker compounds, the next stage will focus on developing this approach into a routine multi-compound screening workflow capable of processing hundreds of samples. Chromeleon CDS software is used to both acquire, process and report results in a seamless workflow that also has a robust audit trial for study accountability. As demonstrated in Figure 9, target compounds can be extracted and quantified. Additional confirmation of a compound presence is achieved through spectral matching of accurate mass fragment ions against in-house or commercial spectral libraries. This is only possible when full scan, accurate mass data is generated, which is why GC-Orbitrap is perfectly suited to this application.
Figure 9. Routine quantitation and confirmation using Chromeleon software.

Summary
The Breath Biopsy Collection Station combined with the TD-GC-Orbitrap represents a complete analytical solution aiming to enable academic and clinical researchers to analyse breath samples in routine and research applications. This approach offers robust sample collection and highly selective data acquisition with complete informatics/data processing and reporting tools so that confident scientific decisions can be made.

The example data presented in this work demonstrate that the Q Exactive GC mass spectrometer delivers consistent accurate mass measurements over a range of analytical conditions. The high resolving power of the system facilitates outstanding mass accuracy, and this combination can be used in a number of application areas where high confidence in compound discovery, screening, identification, and quantification is required.

Retention index information and high resolution filtering during data processing ensure that the large number of features are curated and filtered to meaningful lists containing dense, high-quality data sets. In this example study, breath sample data collected and analyzed via the Breath Biopsy workflow shows high fold changes for two smoking-related markers, suggesting a high correlation between these markers and the smoking habits of the studied subjects.

References